Drug Research

Drug Research is a pharmacology journal from Georg Thieme Verlag in Stuttgart, carrying laboratory and clinical work on how medicines are characterised, tested and monitored, and its 2025 Journal Impact Factor is 2.4.《药物研究》是斯图加特 Georg Thieme Verlag 出版的药学期刊，登载药物表征、检验与监测方面的实验室与临床工作，2025 年期刊影响因子 2.4。

The present name dates from 2013, when the German journal Arzneimittelforschung was relaunched in English, and the volume count still runs back without a gap to the 1951 foundation.现名自 2013 年起使用，当年德文刊 Arzneimittelforschung 以英文重新推出，卷号至今仍不间断地上溯到 1951 年创刊。

Scope

• The published scope opens with analytics as applied to clinical trials, taking in bioanalytical assays, their validation and the handling of samples from the point of collection to the reported concentration.公开的收稿范围首列临床试验中的分析工作，生物分析测定、方法验证与样本从采集到报出浓度之间的处置都在其中。

• Chemistry and biochemistry of active substances come next, covering synthesis, stability and degradation pathways along with the physical characterisation that decides whether a compound can be formulated at all.活性物质的化学与生物化学紧随其后，合成、稳定性与降解途径，以及决定化合物能否成型的物理表征都在这一栏。

• Clinical pharmacology is treated as its own subject, with dose selection, therapeutic drug monitoring and studies run in patients rather than in healthy volunteers alone.临床药理学单列为主题，剂量选择、治疗药物监测与在患者而非只在健康志愿者身上开展的研究都归此栏。

• Experimental pharmacology keeps the laboratory side, from receptor binding and enzyme kinetics to the cell and organ models used to establish a mechanism before any trial begins.实验药理学守住实验室一侧，从受体结合与酶动力学，到试验开始前用来确立机制的细胞与器官模型。

• Drug interactions get a heading of their own, taking in pharmacokinetic interactions through shared metabolic pathways as well as pharmacodynamic ones that appear only when two agents are given together.药物相互作用单设一栏，经由共同代谢通路产生的药代动力学相互作用在列，只有两药合用时才显现的药效学相互作用同样在内。

• Efficacy testing covers comparative studies and dose-response work, together with the re-assessment of established agents against newer comparators whose statistics are judged as part of the science.疗效检验涵盖对照研究与剂量反应试验，也涵盖把老药放到新对照药面前重新评估的工作，其中的统计处理被当作科学的一部分来评。

• Pharmacodynamics receives separate treatment, and papers here are expected to connect the observed effect to a defined target or pathway instead of reporting a response on its own.药效学单独处理，此栏论文须把观察到的效应接到明确靶点或通路上，不能只报一个反应了事。

• Pharmacokinetics takes the absorption and distribution of a drug, adds metabolism and excretion, and goes on to the compartmental and physiologically based models used to predict what a dose will do.药代动力学收下药物在体内的吸收和分布，加上代谢与排泄，再往下是预测某一剂量如何作为的房室模型与生理药代模型。

• Teratology has stayed on the list since the German years, a reminder that reproductive and developmental toxicity was the field in which this title built its first reputation.致畸学自德文时期就在栏目之列，这一项提醒读者，生殖与发育毒性正是本刊最初立足的领域。

• Toxicology closes the subject list, with organ toxicity, safety margins and the preclinical work that has to be finished before a candidate can be taken into humans.毒理学收住主题清单，器官毒性、安全边际与候选药物进入人体前必须做完的临床前工作都在此栏。

• Original articles form the bulk of each issue, and they are expected to report finished work with a stated hypothesis rather than a fragment of a programme still in progress.原创论文构成每期主体，要求报告已完成的工作并写明假设，不能只交一个仍在推进的计划的片段。

• Reviews and short communications sit beside them, the review for a class of agents or a methodological problem and the short piece for a single result that does not need full-paper treatment.综述与研究简报与之并列，综述面向一类药物或一个方法学问题，简报面向无需全文篇幅的单一结果。

• Four shorter formats carry argument rather than data, and the guidelines call them commentary, letter, controversy and opinion paper, each allowed to take a position on a live question.四种短体裁承载论点而非数据，指南把它们称作评论、来信与争议及观点文章，每一种都可以就一个现实问题表态。

• Supplements fall outside the ordinary issue, and the one carried with volume 71 in 2021 gathered German-language proceedings from a symposium on drug therapy in gastroenterology.增刊不占常规期号，2021 年随第 71 卷附出的那一册收录了一场胃肠病药物治疗研讨会的德文报告。

History

• Volume 1 appeared in 1951 under the German title Arzneimittelforschung, and that name stayed on the cover while the journal built its reputation in drug analysis and toxicology.第 1 卷于 1951 年以德文刊名 Arzneimittelforschung 问世，此后这个名称一直留在封面上，刊物在药物分析与毒理学上的名声就是在它下面立起来的。

• Sixty-two volumes had been counted by 2012, and the sixty-third, dated 2013, is the first to carry the English name, the numbering continuing rather than restarting.到 2012 年已累计 62 卷，标 2013 年的第 63 卷是第一种用英文刊名的，卷号接着往下走，没有从头算起。

• The relaunch also changed language, since the body of the journal moved to English while the German-language symposium reports continued to appear in the supplements.改制同时换了语言，正文改用英文，德文研讨会报告则继续在增刊里出现。

• Two sets of numbers exist for the title, and Crossref files 0004-4172 and 1616-7066 under the old name while 2194-9379 and 2194-9387 belong to the new one.刊物前后有两套刊号，Crossref 把 0004-4172 与 1616-7066 记在旧名下，2194-9379 与 2194-9387 归新名。

• Both records now name Georg Thieme Verlag KG of Stuttgart as publisher, the house that runs the journal today and sells it through its own shop.两份记录如今都写着斯图加特的 Georg Thieme Verlag KG 为出版方，这家社今天仍在办这份刊，并在自家商店里销售。

• Volume and year have been in step since the relaunch, so volume 63 is 2013, volume 68 is 2018, volume 71 is 2021 and volume 76 is 2026.改制之后卷号与年份同步，第 63 卷即 2013 年，第 68 卷即 2018 年，第 71 卷即 2021 年，第 76 卷即 2026 年。

• Twelve numbered issues a year were the norm in 2018 and 2019, and each of those two volumes also carried a supplement lettered S 01.2018 年与 2019 年都按一年 12 期出刊，这两卷还各带一册编为 S 01 的增刊。

• Volume 70 in 2020 still reached twelve numbers, but two of them were folded into a single part labelled 02/03, the first sign of the thinning that followed.2020 年的第 70 卷仍编到 12 期，其中两期并作一册，标号 02/03，这是随后收缩的最早迹象。

• From volume 71 in 2021 the journal settled at nine issues a year, and volumes 72, 73 and 74 kept that count without a single deviation.从 2021 年的第 71 卷起，刊物定为一年 9 期，第 72 卷到第 74 卷一期不差地照此办理。

• Volumes 75 and 76 show the count easing again in practice, with paired numbers such as 02/03 and 04/06 standing where separate issues used to sit.第 75 卷与第 76 卷在实际操作里再次松动，02/03 与 04/06 这样的合号顶替了原先的分期。

• MEDLINE picked the new title up with volume 63, number 1, dated January 2013, and the National Library of Medicine has indexed it continuously since then.MEDLINE 从 2013 年 1 月的第 63 卷第 1 期起收录新刊名，美国国家医学图书馆此后一直在编。

• The publisher's index list runs from MEDLINE and BIOSIS Previews through Current Contents and EMBASE to Scopus, with the social science index and the emerging sources index also named.出版方列出的收录库从 MEDLINE 与 BIOSIS Previews 起，经 Current Contents 与 EMBASE 到 Scopus，社会科学索引与新来源索引也在名单上。

• Impact figures have moved upward across three reports, from 1.7 in 2023 to 2.1 in 2024 and 2.4 in 2025, against a five-year value of 2.2.影响因子在三次报告里一路向上，2023 年 1.7，2024 年 2.1，2025 年 2.4，五年值 2.2。

• The 2025 release places it 215th of 356 titles in pharmacology and pharmacy, with 1606 citations counted, a cited half-life of 6.8 years and roughly 30 articles in the window.2025 年榜单把它排在药理学与药学 356 种刊物中的第 215 位，计入被引 1606 次，被引半衰期 6.8 年，窗口内约 30 篇。

• Every article still carries a DOI under 10.1055, the prefix this publisher uses across its whole journal list.每篇文章仍带 10.1055 开头的 DOI，这是该社整个期刊清单通用的前缀。

Editors

• Editorial correspondence is handled from Stuttgart, and the author guidelines send manuscripts to the publisher's office rather than to a named editor's university address.编辑往来由斯图加特的社方处理，作者指南把稿件引向出版社的编辑办公室，而不是某位主编在大学里的地址。

• Every manuscript passes through the house submission platform before it reaches an editor, so reports, revisions and the final decision stay attached to one record for the whole round.稿件先经社方投稿平台登记，再到编辑手上，审稿意见、修回与最终决定在整轮流程里挂在同一份档案上。

• Referees are drawn from pharmacology and toxicology as much as from clinical medicine, which is why a paper with a clean clinical message and a thin analytical section tends to come back before acceptance.审稿人取自药理学与毒理学，也不限于临床医学，因此临床结论干净而分析部分单薄的稿件，往往在录用前就被退回。

• The nine subject areas in the scope list work as an editorial sieve, and a submission that fits none of them may be redirected even when its science is sound.宗旨里的九个学科领域充当编辑初筛，哪一栏都归不进去的稿件即使科学上站得住，也可能被劝转他刊。

• Article type decides the review route, and the guidelines separate a full original article from a short communication by the size of the claim rather than by the word count alone.体裁决定评审路线，指南区分全文与简报的依据是结论的份量，篇幅只算次一等。

• Commentary, letter, controversy and opinion paper are the four places where argument is allowed, and all of them are kept short so that a position is stated rather than a review assembled.评论、来信与争议及观点文章是四个允许论辩的位置，篇幅都压得很短，为的是表明立场，不是攒一篇综述。

• Reviews are commissioned and accepted unsolicited at once, and the ones that work best here take a class of agents or a methodological knot rather than a single disease.综述既约稿也收自由来稿，在本刊站得住的那些，取一类药物或一个方法学难点为题，不在单个病种上铺开。

• Supplements are edited apart from the regular issues, which is how a German-language symposium volume could be carried with volume 71 without disturbing the English main sequence.增刊与常规期分开编辑，德文研讨会专辑能随第 71 卷附出而不打乱英文主序列，靠的就是这条分线。

• The title keeps a standing tie to German experimental and clinical pharmacology, and it presents a Best Short Presentation award at the annual summit of that community.刊物与德国实验及临床药理学界保持长期联系，每年在该界峰会上颁出一个最佳短报告奖。

• Only about one and a half per cent of recent papers have appeared gold open access, so the subscription issue remains the normal route and the open route is an option authors pay for.近年只有约 1.5% 的论文以金色开放获取发表，订阅仍是常规路径，开放只是作者付费另选的一条。

• Indexing is curated for the title as a whole, and the list reaches from MEDLINE and BIOSIS Previews through Current Contents and EMBASE to Scopus and the social science index.收录按整刊办理，清单从 MEDLINE 与 BIOSIS Previews 起，经 Current Contents 与 EMBASE，到 Scopus 与社会科学索引。